Nationwide Survival Benefit after Implementation of First-Line Immunotherapy for Patients with Advanced NSCLC-Real World Efficacy.
Mouritzen MT, Carus A, Ladekarl M, Meldgaard P, Nielsen AWM, Livbjerg A, Larsen JW, Skuladottir H, Kristiansen C, Wedervang K, Schytte T, Hansen KH, Østby AC, Frank MS, Lauritsen J, Sørensen JB, Langer SW, Persson GF, Andersen JL, Frary JMC, Drivsholm LB, Vesteghem C, Christensen HS, Bjørnhart B, Pøhl M.
Mouritzen MT, et al. Among authors: ladekarl m.
Cancers (Basel). 2021 Sep 28;13(19):4846. doi: 10.3390/cancers13194846.
Cancers (Basel). 2021.
PMID: 34638329
Free PMC article.